NL195004C - Fenylcarbamaat bevattend farmaceutisch preparaat. - Google Patents

Fenylcarbamaat bevattend farmaceutisch preparaat. Download PDF

Info

Publication number: NL195004C
Authority: NL; Netherlands
Prior art keywords: ethyl; compound; formula; carbon atoms; pharmaceutical
Prior art date: 1987-03-04

Application number

NL8800436A

Other languages

English (en)

Dutch (nl)

Other versions

NL8800436A (nl

NL195004B (nl

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-03-04

Filing date

1988-02-22

Publication date

2003-11-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6322236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL195004(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1988-02-22 Application filed by Novartis Ag filed Critical Novartis Ag

1988-10-03 Publication of NL8800436A publication Critical patent/NL8800436A/nl

2003-05-01 Priority to NL9900033A priority Critical patent/NL195081C/nl

2003-07-01 Publication of NL195004B publication Critical patent/NL195004B/nl

2003-11-04 Application granted granted Critical

2003-11-04 Publication of NL195004C publication Critical patent/NL195004C/nl

Links

239000000825 pharmaceutical preparation Substances 0.000 title claims description 6
BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims description 19
239000008194 pharmaceutical composition Substances 0.000 claims description 9
102100033639 Acetylcholinesterase Human genes 0.000 claims description 8
108010022752 Acetylcholinesterase Proteins 0.000 claims description 8
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
229910052739 hydrogen Inorganic materials 0.000 claims description 7
239000001257 hydrogen Substances 0.000 claims description 7
125000000217 alkyl group Chemical group 0.000 claims description 6
125000004432 carbon atom Chemical group C* 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
239000007787 solid Substances 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 5
239000012458 free base Substances 0.000 claims description 5
150000002431 hydrogen Chemical group 0.000 claims description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
229940022698 acetylcholinesterase Drugs 0.000 claims description 3
239000002674 ointment Substances 0.000 claims description 3
FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 claims description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 2
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
229910052757 nitrogen Inorganic materials 0.000 claims description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
239000008024 pharmaceutical diluent Substances 0.000 claims description 2
XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical group O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 claims description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
239000002552 dosage form Substances 0.000 claims 1
230000002401 inhibitory effect Effects 0.000 claims 1
230000009897 systematic effect Effects 0.000 claims 1
239000013543 active substance Substances 0.000 description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
239000003814 drug Substances 0.000 description 7
229940079593 drug Drugs 0.000 description 7
230000000694 effects Effects 0.000 description 7
239000000203 mixture Substances 0.000 description 7
241000234282 Allium Species 0.000 description 6
229940126062 Compound A Drugs 0.000 description 6
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
235000002732 Allium cepa var. cepa Nutrition 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
241000700159 Rattus Species 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
230000035515 penetration Effects 0.000 description 4
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
229920001477 hydrophilic polymer Polymers 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
230000036765 blood level Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
QYOVMAREBTZLBT-KTKRTIGZSA-N CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO QYOVMAREBTZLBT-KTKRTIGZSA-N 0.000 description 1
229920003149 Eudragit® E 100 Polymers 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
230000037374 absorbed through the skin Effects 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000000544 cholinesterase inhibitor Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000011888 foil Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000000155 melt Substances 0.000 description 1
238000000034 method Methods 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000011505 plaster Substances 0.000 description 1
239000002985 plastic film Substances 0.000 description 1
229920006255 plastic film Polymers 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920006267 polyester film Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
-1 toluyl tartaric acid monohydrate Chemical compound 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

NL8800436A 1987-03-04 1988-02-22 Fenylcarbamaat bevattend farmaceutisch preparaat. NL195004C (nl)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
NL9900033A NL195081C (nl)	1987-03-04	2003-05-01	Fenylcarbamaat.

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE3706914		1987-03-04
DE3706914		1987-03-04

Publications (3)

Publication Number	Publication Date
NL8800436A NL8800436A (nl)	1988-10-03
NL195004B NL195004B (nl)	2003-07-01
NL195004C true NL195004C (nl)	2003-11-04

Family

ID=6322236

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8800436A NL195004C (nl)	1987-03-04	1988-02-22	Fenylcarbamaat bevattend farmaceutisch preparaat.

Country Status (29)

Country	Link
US (1)	US5602176A (2)
JP (3)	JP2625478B2 (2)
KR (1)	KR0133686B1 (2)
AT (1)	AT394190B (2)
AU (1)	AU618949B2 (2)
BE (1)	BE1001467A3 (2)
CA (1)	CA1307003C (2)
CH (1)	CH675720A5 (2)
CS (1)	CS411091A3 (2)
CY (1)	CY1735A (2)
DK (1)	DK175762B1 (2)
ES (1)	ES2010527A6 (2)
FI (1)	FI89165C (2)
FR (1)	FR2611707B1 (2)
GB (1)	GB2203040C (2)
GR (1)	GR1000023B (2)
HK (1)	HK110093A (2)
HU (1)	HU201906B (2)
IE (1)	IE61714B1 (2)
IL (1)	IL85609A (2)
IT (1)	IT1219853B (2)
LU (2)	LU87150A1 (2)
MY (1)	MY103225A (2)
NL (1)	NL195004C (2)
NZ (1)	NZ223714A (2)
PT (1)	PT86875B (2)
SA (1)	SA93140384B1 (2)
SE (1)	SE8800731L (2)
ZA (1)	ZA881584B (2)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU201906B (en) *	1987-03-04	1991-01-28	Sandoz Ag	Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
AU2224195A (en) *	1994-04-15	1995-11-10	Masaomi Iyo	Medicinal composition for treating tardive dyskinesia and utilization thereof
US6251938B1 (en)	1996-12-18	2001-06-26	Teva Pharmaceutical Industries, Ltd.,	Phenylethylamine derivatives
WO1998026775A1 (en) *	1996-12-18	1998-06-25	Teva Pharmaceutical Industries, Ltd.	Phenylethylamine derivatives
ES2241064T3 (es)	1996-12-18	2005-10-16	Teva Pharmaceutical Industries, Ltd.	Derivados de aminoindano.
GB9800526D0 (en)	1998-01-12	1998-03-11	Ciba Geigy Ag	Organic compounds
US6316023B1 (en) *	1998-01-12	2001-11-13	Novartis Ag	TTS containing an antioxidant
US6218383B1 (en)	1998-08-07	2001-04-17	Targacept, Inc.	Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
BR9914251A (pt)	1998-10-01	2001-06-19	Novartis Ag	Formulações orais de liberação sustentada
US20040209849A1 (en) *	1998-11-27	2004-10-21	Sanochemia Pharmazeutika Aktiengesellschaft	Use of effectors of the central cholinergic nervous system for treatment of delirium
JP2002531502A (ja) *	1998-12-11	2002-09-24	デイビス、ボニー	視床下部−下垂体−生殖腺軸変調に於けるアセチルコリンエステラーゼ阻害剤の使用
GB9923045D0 (en) *	1999-09-29	1999-12-01	Novartis Ag	New oral formulations
US6534541B1 (en) *	1999-10-19	2003-03-18	Novartis Ag	Treatment of ocular disorders
AU5702201A (en) *	2000-04-13	2001-10-30	Mayo Foundation	Abeta<sub>42</sub> lowering agents
US20040010038A1 (en) *	2002-02-27	2004-01-15	Eran Blaugrund	Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
CZ20023555A3 (cs)	2002-10-24	2004-01-14	Léčiva, A.S.	Způsob výroby (-)-(S)-3-[1-(dimethylamino)ethyl]fenyl-N-ethyl-N-methylkarbamátu
KR100777904B1 (ko) *	2002-10-24	2007-11-28	메르츠 파마 게엠베하 운트 코. 카가아	1-아미노시클로헥산 유도체 및 아세틸콜린에스테라제 저해제를 포함하는 약학적 제품 및 이를 이용한 복합 치료
WO2004071431A2 (en) *	2003-02-05	2004-08-26	Myriad Genetics, Inc.	Method and composition for treating neurodegenerative disorders
US7521481B2 (en)	2003-02-27	2009-04-21	Mclaurin Joanne	Methods of preventing, treating and diagnosing disorders of protein aggregation
KR20060040676A (ko) *	2003-07-11	2006-05-10	미리어드 제네틱스, 인크.	알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
US7795307B2 (en) *	2003-10-21	2010-09-14	Colucid Pharmaceuticals, Inc.	Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
GB2409453A (en) *	2003-12-24	2005-06-29	Generics	Process for the preparation of aminoalkyl phenylcarbamates
WO2006001877A2 (en) *	2004-04-13	2006-01-05	Myriad Genetics, Inc.	Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
AU2005241023A1 (en) *	2004-04-29	2005-11-17	Keystone Retaining Wall Systems, Inc.	Veneers for walls, retaining walls and the like
EP1779867A4 (en) *	2004-07-01	2009-12-02	Eisai R&D Man Co Ltd	MEANS FOR PROMOTING NERVE REVENERATION
WO2006020853A2 (en) *	2004-08-11	2006-02-23	Myriad Genetics, Inc.	Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) *	2004-08-11	2006-02-23	Myriad Genetics, Inc.	Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) *	2004-08-11	2006-02-23	Myriad Genetics, Inc.	Pharmaceutical composition and method for treating neurodegenerative disorders
RU2393148C2 (ru) *	2004-11-08	2010-06-27	Эмкюр Фармасьютикалз Лимитед	Способ получения (s)-3-[(1-диметиламино)этил]-фенил-n-этил-n-метил-карбамата
GB0507298D0 (en)	2005-04-11	2005-05-18	Novartis Ag	Organic compounds
KR20080039876A (ko) *	2005-07-22	2008-05-07	미리어드 제네틱스, 인크.	높은 약물 충진 제형 및 투여형
ES2267399B1 (es)	2005-08-04	2008-02-01	Ragactives, S.L.	Procedimiento para la obtencion de carbamatos de fenilo.
JP5116679B2 (ja)	2005-09-15	2013-01-09	株式会社ソニー・コンピュータエンタテインメント	強度のコンピュータ画像および音声処理、ならびにコンピュータプログラムとインタフェースするための入力装置
TWI389709B (zh) *	2005-12-01	2013-03-21	Novartis Ag	經皮治療系統
ES2632638T3 (es) *	2005-12-09	2017-09-14	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Ladostigilo de baja dosis para el tratamiento de la deficiencia cognitiva
TW200744576A (en) *	2006-02-24	2007-12-16	Teva Pharma	Propargylated aminoindans, processes for preparation, and uses thereof
US7767843B2 (en) *	2006-03-02	2010-08-03	Apotex Pharmachem Inc.	Process for the preparation of phenylcarbamates
EP2046119A2 (en) *	2006-07-07	2009-04-15	Myriad Genetics, Inc.	Treatment of psychiatric disorders
CA2661009A1 (en) *	2006-08-17	2008-02-21	Alembic Limited	Improved process for the preparation of rivastigmine
WO2008037433A1 (en)	2006-09-29	2008-04-03	Synthon B.V.	Process for making aminoalkylphenyl carbamates and intermediates therefor
AU2007309390A1 (en)	2006-10-27	2008-05-02	Medivation Neurology, Inc.	Methods and combination therapies for treating Alzheimer's disease
EP1942100A1 (en) *	2007-01-04	2008-07-09	Krka Tovarna Zdravil, D.D., Novo Mesto	Amorphous and crystalline forms of rivastigmine hydrogentartrate
AU2008214380A1 (en) *	2007-02-02	2008-08-14	Colucid Pharmaceuticals, Inc.	Compounds that inhibit cholinesterase
US8013181B2 (en) *	2007-04-10	2011-09-06	Dr. Reddy's Laboratories Limited	Preparation of rivastigmine and its salts
WO2008124969A1 (en) *	2007-04-16	2008-10-23	Topharman Shanghai Co., Ltd.	Preparation method of rivastigmine and its intermediates
US7884121B2 (en) *	2007-06-11	2011-02-08	Apotex Pharmachem Inc.	Process for the preparation of phenylcarbamates
JP2010533717A (ja) *	2007-07-18	2010-10-28	コルシド・ファーマシューティカルズ・インコーポレイテッド	覚醒を促進する方法
US8593728B2 (en) *	2009-02-19	2013-11-26	Toyota Motor Engineering & Manufacturing North America, Inc.	Multilayer photonic structures
US20090082436A1 (en) *	2007-09-26	2009-03-26	Protia, Llc	Deuterium-enriched rivastigmine
CN101910110B (zh) *	2008-01-10	2013-05-22	上海医药工业研究院	利凡斯的明的制备方法、其中间体以及中间体的制备方法
US8420846B2 (en)	2008-08-25	2013-04-16	Jubilant Life Sciences Limited	Process for producing (S)-3-[(1-dimethylamino)ethyl] phenyl-N-ethyl-N-methyl-carbamate via novel intermediates
US20100087768A1 (en) *	2008-10-02	2010-04-08	Forlano Paula	Transdermal drug delivery system for liquid active ingredient
GB0823554D0 (en)	2008-12-24	2009-01-28	Novartis Ag	Process for the preparation of optically active compounds using transfer hydrogenation
CN101823970B (zh) *	2009-03-03	2013-05-08	江苏恩华药业股份有限公司	卡巴拉汀及其中间体的合成方法
ES2670227T3 (es)	2009-12-22	2018-05-29	Luye Pharma Ag	Sistema terapéutico transdérmico para la administración de rivastigmina o sus derivados
US10076502B2 (en)	2009-12-22	2018-09-18	Luye Pharma Ag	Transdermal therapeutic system for administering rivastigmine or derivatives thereof
ES2363395B1 (es) *	2010-01-20	2012-02-23	Farmalider, S.A.	Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
EA202092673A3 (ru) *	2010-02-09	2021-05-31	Дзе Джонс Хопкинс Юниверсити	Способы и композиции для улучшения когнитивной функции
BR112012024708A2 (pt)	2010-03-29	2016-06-07	Novartis Ag	composição de compostos orgânicos
WO2011151669A1 (en)	2010-06-02	2011-12-08	Jubilant Life Sciences Limited	Process for producing enantiomerically enriched isomer of 3-(1-aminoethyl) phenyl derivative and employing the same to produce rivastigmine or its pharmaceutically acceptable salt
WO2011151359A1 (en)	2010-06-02	2011-12-08	Noscira, S.A.	Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
DK2582799T3 (en)	2010-06-17	2018-02-12	Codexis Inc	BIOCATALATORS AND PROCEDURES FOR THE SYNTHESIS OF (S) -3- (1-AMINOETHYL) -PHENOL
EP3034079B1 (en)	2010-11-15	2018-01-10	Agenebio, Inc.	Pyridazine derivatives, compositions and methods for treating cognitive impairment
DK2468274T3 (en)	2010-12-14	2015-08-31	Acino Ag	Transdermal therapeutic system for administration of an active substance
CN102786441B (zh) *	2011-05-18	2013-11-13	浙江海正药业股份有限公司	利凡斯的明的制备方法、其中间体以及中间体的制备方法
BR112013029945A2 (pt)	2011-05-20	2017-01-31	Sk Chemicals Co Ltd	emplastro contendo rivastigmina
AR082640A1 (es) *	2011-08-25	2012-12-19	Amarin Technologies S A	Un dispositivo para la administracion transdermal de compuestos alcalinos susceptibles a la degradacion en su forma no salificada
JP6102739B2 (ja)	2011-08-31	2017-03-29	東洋インキＳｃホールディングス株式会社	貼付剤
CN103073456B (zh) *	2011-10-26	2014-03-19	连云港润众制药有限公司	重酒石酸卡巴拉汀中间体的制备方法
EP2594261A1 (en)	2011-11-18	2013-05-22	Labtec GmbH	Composition for transdermal administration of rivastigmine
WO2013142339A1 (en)	2012-03-23	2013-09-26	Novartis Ag	Transdermal therapeutic system and method
ES2449215B1 (es) *	2012-09-17	2014-07-14	Galenicum Health S.L.	Solución oral de (S)-3-[1-(dimetilamino)etil]fenil N-etil-N-metilcarbamato
KR20140038237A (ko)	2012-09-20	2014-03-28	에스케이케미칼주식회사	리바스티그민의 안정성이 개선된 의약품
US20140206667A1 (en)	2012-11-14	2014-07-24	Michela Gallagher	Methods and compositions for treating schizophrenia
CN103896787A (zh) *	2012-12-26	2014-07-02	江苏康倍得药业有限公司	一种卡巴拉汀前体[1-(3-甲氧基苯基)乙基]二甲胺的制备方法
WO2014111790A2 (en)	2013-01-15	2014-07-24	Zydus Technologies Limited	Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
AU2014228512A1 (en)	2013-03-15	2015-10-01	Agenebio, Inc.	Methods and compositions for improving cognitive function
WO2014144663A1 (en)	2013-03-15	2014-09-18	The Johns Hopkins University	Methods and compositions for improving cognitive function
CN103319374B (zh) *	2013-06-09	2015-04-22	无锡佰翱得生物科学有限公司	一种(s)-卡巴拉汀的不对称合成方法
AU2014307803A1 (en)	2013-08-16	2016-03-10	Universiteit Maastricht	Treatment of cognitive impairment with PDE4 inhibitor
EP3083569B1 (en)	2013-12-20	2022-01-26	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CA2986598C (en)	2015-05-22	2023-09-26	Agenebio, Inc.	Extended release pharmaceutical compositions of levetiracetam
JP6987384B2 (ja)	2015-06-19	2021-12-22	エージンバイオ，インコーポレイテッド	ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
US11505555B2 (en)	2016-12-19	2022-11-22	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en)	2016-12-19	2018-06-21	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11414425B2 (en)	2018-06-19	2022-08-16	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
KR20200035359A (ko)	2018-09-26	2020-04-03	캐딜라 파마슈티클즈 리미티드	리바스티그민 제조용 중간체의 합성
WO2024039886A1 (en)	2022-08-19	2024-02-22	Agenebio, Inc.	Benzazepine derivatives, compositions, and methods for treating cognitive impairment
WO2025038382A1 (en)	2023-08-11	2025-02-20	Momentive Performance Materials Inc.	Pharmaceutical adhesive compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4469700A (en) *	1981-06-19	1984-09-04	Lowell M. Somers	Benzoylecgonine or benzoylnorecgonine as active agents for the treatment of rheumatoid arthritis
IL74497A (en) *	1985-03-05	1990-02-09	Proterra Ag	Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
HU201906B (en) *	1987-03-04	1991-01-28	Sandoz Ag	Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them

1988
- 1988-02-22 HU HU88827A patent/HU201906B/hu unknown
- 1988-02-22 NL NL8800436A patent/NL195004C/nl not_active IP Right Cessation
- 1988-02-29 BE BE8800230A patent/BE1001467A3/fr not_active IP Right Cessation
- 1988-02-29 FR FR888802597A patent/FR2611707B1/fr not_active Expired - Lifetime
- 1988-03-01 CH CH774/88A patent/CH675720A5/de not_active IP Right Cessation
- 1988-03-01 GB GB8804888A patent/GB2203040C/en not_active Expired - Lifetime
- 1988-03-02 AU AU12554/88A patent/AU618949B2/en not_active Expired
- 1988-03-02 NZ NZ223714A patent/NZ223714A/en unknown
- 1988-03-02 SE SE8800731A patent/SE8800731L/xx not_active Application Discontinuation
- 1988-03-02 LU LU87150A patent/LU87150A1/fr active Protection Beyond IP Right Term
- 1988-03-02 IL IL85609A patent/IL85609A/xx not_active IP Right Cessation
- 1988-03-02 IE IE58388A patent/IE61714B1/en not_active IP Right Cessation
- 1988-03-02 PT PT86875A patent/PT86875B/pt active IP Right Grant
- 1988-03-02 FI FI880972A patent/FI89165C/fi active Protection Beyond IP Right Term
- 1988-03-02 DK DK198801125A patent/DK175762B1/da not_active IP Right Cessation
- 1988-03-03 KR KR1019880002187A patent/KR0133686B1/ko not_active Expired - Lifetime
- 1988-03-03 CA CA000560457A patent/CA1307003C/en not_active Expired - Lifetime
- 1988-03-03 JP JP63052478A patent/JP2625478B2/ja not_active Expired - Lifetime
- 1988-03-03 GR GR880100125A patent/GR1000023B/el not_active IP Right Cessation
- 1988-03-03 AT AT0055188A patent/AT394190B/de not_active IP Right Cessation
- 1988-03-03 MY MYPI88000215A patent/MY103225A/en unknown
- 1988-03-04 ES ES8800651A patent/ES2010527A6/es not_active Expired
- 1988-03-04 ZA ZA881584A patent/ZA881584B/xx unknown
- 1988-03-04 IT IT47693/88A patent/IT1219853B/it active Protection Beyond IP Right Term
1991
- 1991-12-27 CS CS914110A patent/CS411091A3/cs unknown
1993
- 1993-10-21 HK HK1100/93A patent/HK110093A/xx not_active IP Right Cessation
- 1993-11-29 SA SA93140384A patent/SA93140384B1/ar unknown
1994
- 1994-06-03 CY CY173594A patent/CY1735A/en unknown
1995
- 1995-06-06 US US08/466,502 patent/US5602176A/en not_active Expired - Lifetime
1996
- 1996-09-12 JP JP8241702A patent/JPH09118617A/ja active Pending
- 1996-11-01 JP JP8291560A patent/JP2859225B2/ja not_active Expired - Lifetime
1998
- 1998-10-07 LU LU90297C patent/LU90297I2/fr unknown

Also Published As

Publication number	Publication date
KR880011088A (ko)	1988-10-26
IL85609A (en)	1992-07-15
SA93140384B1 (ar)	2006-04-04
CA1307003C (en)	1992-09-01
GB2203040C (en)	2014-07-30
HU201906B (en)	1991-01-28
JPH09165362A (ja)	1997-06-24
LU87150A1 (fr)	1988-11-17
AT394190B (de)	1992-02-10
FI880972A0 (fi)	1988-03-02
ATA55188A (de)	1991-08-15
DK112588D0 (da)	1988-03-02
JP2625478B2 (ja)	1997-07-02
JP2859225B2 (ja)	1999-02-17
IL85609A0 (en)	1988-08-31
FI880972L (fi)	1988-09-05
GB2203040B (en)	1990-10-24
FR2611707B1 (fr)	1990-04-20
AU618949B2 (en)	1992-01-16
JPS63238054A (ja)	1988-10-04
FI89165B (fi)	1993-05-14
GB8804888D0 (en)	1988-03-30
NL8800436A (nl)	1988-10-03
IT1219853B (it)	1990-05-24
HK110093A (en)	1993-10-29
SE8800731A0 (sv)	1988-09-05
US5602176A (en)	1997-02-11
PT86875B (pt)	1992-05-29
HUT49325A (en)	1989-09-28
GR880100125A (en)	1989-01-31
SE8800731D0 (sv)	1988-03-02
DK175762B1 (da)	2005-02-14
KR0133686B1 (ko)	1998-04-21
IT8847693A0 (it)	1988-03-04
CY1735A (en)	1994-06-03
FI89165C (fi)	1993-08-25
IE61714B1 (en)	1994-11-30
DK112588A (da)	1988-09-05
BE1001467A3 (fr)	1989-11-07
JPH09118617A (ja)	1997-05-06
PT86875A (pt)	1988-04-01
LU90297I2 (fr)	1998-12-07
NZ223714A (en)	1994-05-26
CH675720A5 (2)	1990-10-31
IE880583L (en)	1988-09-04
AU1255488A (en)	1988-09-08
ZA881584B (en)	1989-11-29
GB2203040A (en)	1988-10-12
FR2611707A1 (fr)	1988-09-09
NL195004B (nl)	2003-07-01
ES2010527A6 (es)	1989-11-16
CS411091A3 (en)	1992-12-16
SE8800731L (sv)	1988-09-05
GR1000023B (el)	1990-01-31
MY103225A (en)	1993-05-29

Legal Events

Date	Code	Title	Description
1995-03-01	BA	A request for search or an international-type search has been filed
1995-05-01	BB	A search report has been drawn up
1996-01-02	BC	A request for examination has been filed
1997-11-03	CNR	Transfer of rights (patent application after its laying open for public inspection)	Free format text: NOVARTIS AG
2008-04-01	V4	Discontinued because of reaching the maximum lifetime of a patent	Effective date: 20080222

Publication	Publication Date	Title
NL195004C (nl)	2003-11-04	Fenylcarbamaat bevattend farmaceutisch preparaat.
KR0136870B1 (ko)	1998-04-25	전신적 경피 투여용 약학적 조성물
EP0221753B1 (en)	1992-01-08	Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
EP2504311B1 (en)	2015-08-12	Arachidonic acid analogs and methods for analgesic treatment using same
PT1962817E (pt)	2010-12-13	Administração transdérmica de uma forma de sal de meptazinol
BRPI0621655A2 (pt)	2011-12-20	preparação para a absorção percutánea de uma droga antidemência básica
PT1178782E (pt)	2006-12-29	Sistema terapêutico transdérmico ( tts ) contendo tolterodina
JPH03236317A (ja)	1991-10-22	ドパミン誘導体含有経皮用製剤
LV10386B (en)	1995-12-20	Pharmaceutical composition and process for the preparation thereof
NZ301197A (en)	1999-09-29	Transdermal formulation of xanomeline for treating alzeheimers disease
CA2513708C (en)	2011-01-04	Formulation and methods for the treatment of thrombocythemia
KR100764679B1 (ko)	2007-10-09	파록세틴을 함유하는 경피투여용 패취제
AU706814B2 (en)	1999-06-24	Deuterated active substances in transdermal application
FR2556216A1 (fr)	1985-06-14	Nouveau medicament analgesique contenant du proglumide, eventuellement en association avec des medicaments analgesiques-narcotiques
JPH11507326A (ja)	1999-06-29	腫瘍組織の選択的治療用医薬物質
KR101244799B1 (ko)	2013-03-18	신경퇴행성 병을 치료하기 위한 ｎ-피페리딘 유도체의 용도
JP2521091B2 (ja)	1996-07-31	カテコ−ルアミン類の外用製剤
KR20070059079A (ko)	2007-06-11	경피 페로스피론 투여용 의약적 조성물
EP4153151B1 (en)	2023-11-22	Slow-release medical plaster
NL195081C (nl)	2003-09-22	Fenylcarbamaat.
RU2193555C2 (ru)	2002-11-27	Метил-изопропил[(3-н-пропоксифенокси)этил]амин или его фармацевтически приемлемая соль, способы его получения (варианты), фармацевтическая композиция, способ местной анестезии
JPH01153633A (ja)	1989-06-15	経皮吸収製剤
CA1263843A (en)	1989-12-12	Treatment of sleep disorders
HK32494A (en)	1994-04-07	Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
Albert	1985	Comparative distribution: the first principle of selectivity